Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated ...

Chardan slashed the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) on May 27, lowering it to $18 from $40 ...

Prothena (PRTA – Research Report) received a Hold rating and price target from Oppenheimer analyst Jay Olson yesterday. The company’s shares closed last Friday at $6.58. Confi ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Prothena (PRTA – Research Report) and Bristol-Myers Squibb (BMY – Research Report). Confident ...

Fintel reports that on May 27, 2025, Oppenheimer downgraded their outlook for Prothena (NasdaqGS:PRTA) from Outperform to Perform. Analyst Price Forecast Suggests 1,057.57% Upside As of May 7, 2025, ...